Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zile

Showing results (751-760 of 1,060) with videos related to

Pageof 106
Sort By:
American Heart Journal|August 1, 2006
Rationale and design: the VALsartan In Diastolic Dysfunction (VALIDD) Trial: evolving the management of diastolic dysfunction in hypertensionRajesh Janardhanan, William L Daley, Tasneem Z Naqvi, et al.
Circulation. Heart Failure|April 14, 2025
Relationship Between Remote, Ambulatory Pulmonary Artery Pressures, and All-Cause Mortality in Patients With Chronic Heart FailureMichael R Zile, William T Abraham, Lynne W Stevenson, et al.
The American Journal of Medicine|January 22, 2013
Renin-angiotensin inhibition in diastolic heart failure and chronic kidney diseaseAli Ahmed, Michael W Rich, Michael Zile, et al.
European Journal of Heart Failure|June 11, 2021
Influence of study discontinuation during the run-in period on the estimated efficacy of sacubitril/valsartan in the PARAGON-HF trialKota Suzuki, Brian Claggett, Masatoshi Minamisawa, et al.
Journal of the American College of Cardiology|February 22, 2023
Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With Heart FailureSafia Chatur, Brian L Claggett, Finnian R McCausland, et al.
JACC. Heart Failure|January 10, 2016
Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF TrialOrly Vardeny, Brian Claggett, Jacob A Udell, et al.
European Journal of Heart Failure|February 12, 2019
Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trialOrly Vardeny, Brian Claggett, Jessica Kachadourian, et al.
JAMA Cardiology|November 29, 2018
Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF TrialPratyaksh K Srivastava, Brian L Claggett, Scott D Solomon, et al.
European Journal of Heart Failure|May 15, 2020
Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fractionKota Suzuki, Brian Claggett, Masatoshi Minamisawa, et al.
Journal of the American Heart Association|October 11, 2024
Personalized Intervention Strategy Based on a Risk Score Generated From Subcutaneous Insertable Cardiac Monitor: Results From Phase 1 of ALLEVIATE-HFRami Kahwash, Michael R Zile, Prasad Chalasani, et al.
Pageof 106

Showing results (751-760 of 1,060) with videos related to

Sort By:
Pageof 106
American Heart Journal|August 1, 2006
Rationale and design: the VALsartan In Diastolic Dysfunction (VALIDD) Trial: evolving the management of diastolic dysfunction in hypertensionRajesh Janardhanan, William L Daley, Tasneem Z Naqvi, et al.
Circulation. Heart Failure|April 14, 2025
Relationship Between Remote, Ambulatory Pulmonary Artery Pressures, and All-Cause Mortality in Patients With Chronic Heart FailureMichael R Zile, William T Abraham, Lynne W Stevenson, et al.
The American Journal of Medicine|January 22, 2013
Renin-angiotensin inhibition in diastolic heart failure and chronic kidney diseaseAli Ahmed, Michael W Rich, Michael Zile, et al.
European Journal of Heart Failure|June 11, 2021
Influence of study discontinuation during the run-in period on the estimated efficacy of sacubitril/valsartan in the PARAGON-HF trialKota Suzuki, Brian Claggett, Masatoshi Minamisawa, et al.
Journal of the American College of Cardiology|February 22, 2023
Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With Heart FailureSafia Chatur, Brian L Claggett, Finnian R McCausland, et al.
JACC. Heart Failure|January 10, 2016
Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF TrialOrly Vardeny, Brian Claggett, Jacob A Udell, et al.
European Journal of Heart Failure|February 12, 2019
Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trialOrly Vardeny, Brian Claggett, Jessica Kachadourian, et al.
JAMA Cardiology|November 29, 2018
Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF TrialPratyaksh K Srivastava, Brian L Claggett, Scott D Solomon, et al.
European Journal of Heart Failure|May 15, 2020
Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fractionKota Suzuki, Brian Claggett, Masatoshi Minamisawa, et al.
Journal of the American Heart Association|October 11, 2024
Personalized Intervention Strategy Based on a Risk Score Generated From Subcutaneous Insertable Cardiac Monitor: Results From Phase 1 of ALLEVIATE-HFRami Kahwash, Michael R Zile, Prasad Chalasani, et al.
Pageof 106